Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Revolution Medicines (RVMD) Shares Outstanding (Weighted Average) (2018 - 2025)

Revolution Medicines has reported Shares Outstanding (Weighted Average) over the past 8 years, most recently at $190.1 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $190.1 million for Q4 2025, up 13.35% from a year ago — trailing twelve months through Dec 2025 was $190.1 million (up 13.35% YoY), and the annual figure for FY2025 was $190.1 million, up 13.35%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $190.1 million at Revolution Medicines, roughly flat from $189.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for RVMD hit a ceiling of $190.1 million in Q4 2025 and a floor of $70.4 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $105.1 million (2023), compared with a mean of $121.6 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 140.36% in 2021 and later rose 3.2% in 2022.
  • Revolution Medicines' Shares Outstanding (Weighted Average) stood at $72.8 million in 2021, then rose by 10.74% to $80.6 million in 2022, then soared by 40.34% to $113.1 million in 2023, then skyrocketed by 48.24% to $167.7 million in 2024, then increased by 13.35% to $190.1 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $190.1 million (Q4 2025), $189.2 million (Q3 2025), and $188.4 million (Q2 2025) per Business Quant data.